^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

    Excerpt:
    ...Confirmed diagnosis of a malignancy harbouring any actionable BRAF V600 mutation using an analytically validated sequencing technique (result does...
    Trial ID:
    DETERMINE
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cancer Chemother Pharmacol
    Title:

    Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

    Published date:
    05/22/2022
    Excerpt:
    Tumor histopathology revealed the presence of a double tumor; a BRAF V600-mutated T4aN1bM0 papillary thyroid carcinoma...The patient was thereafter included in the DRUP trial and received vemurafenib/cobimetinib combination treatment, targeting the BRAF mutation....After two treatment cycles the first response evaluation, using Response Evaluation Criteria in Solid Tumors (RECIST v1.1), showed a partial response with a decrease of 45% in sum of target lesions.
    DOI:
    10.1007/s00280-022-04437-z